2017 ASCO Annual Meeting!
Session: Patient and Survivor Care
Type: Poster Session
Time: Saturday June 3, 1:15 PM to 4:45 PM
Location: Hall A
The importance of recognizing and addressing depression in patients with advanced cancer.
Patient and Survivor Care
2017 ASCO Annual Meeting
Poster Board Number:
Poster Session (Board #39)
J Clin Oncol 35, 2017 (suppl; abstr 10050)
Author(s): Risa Wong, Areej El-Jawahri, Kelly Irwin, Sara D'Arpino, Samantha M.C. Moran, Connor Johnson, Daniel Lage, Margaret Ruddy, Brandon Temel, Lara Traeger, Inga Tolin Lennes, Barbara J. Cashavelly, Holly S Martinson, Vicki Jackson, Joseph A. Greer, David P. Ryan, Ephraim P. Hochberg, William F. Pirl, Jennifer S. Temel, Ryan David Nipp; Massachusetts General Hospital, Boston, MA; Massachusetts General Hospital Cancer Center, Boston, MA; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL
Background: Patients with cancer often experience depression, which is associated with worse outcomes, including longer hospital length of stay (LOS). Although antidepressant medication can improve depressive symptoms in patients with cancer, it is unclear whether their use translates into better outcomes. We sought to clarify the relationship between depressive symptoms, antidepressant medication, and hospital LOS in patients with advanced cancer. Methods: We enrolled hospitalized patients with advanced cancer from 9/2014 to 4/2016 as part of a longitudinal data repository. We examined patients’ medical records to obtain information about documented depressive symptoms in the 3 months prior to admission and use of antidepressant medication at the time of admission. Using descriptive statistics, we compared differences in patient characteristics and hospital LOS across these groups. We used linear regression to examine associations and moderation effects between depressive symptoms, use of antidepressant medication, and hospital LOS. Results: Of 1,036 enrolled patients (89.9% of approached), 126 (12.2%) had documented depressive symptoms in the 3 months prior to admission and 288 (27.8%) were taking an antidepressant medication at the time of admission. Patients with depressive symptoms were more likely to be on antidepressant medication at admission than those without depressive symptoms (48.4% vs 24.9%, p < .001). Patients taking antidepressant medication were younger (62.4 vs 64.4 years, p = .026) and more likely to be female (55.2% vs 47.2%, p = .021). Depressive symptoms were associated with longer hospital LOS (7.3 vs 6.1 days, p = .036), and antidepressant medication was a moderator of this relationship. Among patients not on antidepressant medication, depressive symptoms were associated with longer hospital LOS (7.9 vs 6.1 days, p = .025), but among those on antidepressant medication, depressive symptoms were not associated with hospital LOS (6.6 vs 6.2 days, p = .588). Conclusions: Antidepressant medication moderated the relationship between depressive symptoms and longer hospital LOS. Our results support the need to recognize and address depressive symptoms in patients with advanced cancer.